AKT1 and neoplasm: Furthermore, GZ17-6.02 itself is shown to suppress expression of mTORC1 and AKT proteins in vitro and in murine models and the topical formulation of the medication, GZ21T, was shown to inhibits the Pi3K/Akt pathway in a UVB-induced model of skin carcinogenesis19,25,26,71.